Comparative Pharmacokinetics, Bioequivalence and Safety Study of Two Recombinant Human Chorionic Gonadotropin Injections in Healthy Chinese Subjects
Authors Wang J, Yang T, Mei H, Yu X, Peng H, Wang R, Cai Y
Received 17 October 2019
Accepted for publication 31 December 2019
Published 29 January 2020 Volume 2020:14 Pages 435—444
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Anastasios Lymperopoulos
Jin Wang,1,* Tianli Yang,1,* Hekun Mei,1 Xueming Yu,2 Hongmei Peng,3 Rui Wang,1 Yun Cai1
1Center of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing 100853, People’s Republic of China; 2Livzon MabPharm Inc, Zhuhai, Guangdong 519045, People’s Republic of China; 3Reproductive Medicine Center, Department of Obstetrics and Gynecology, PLA General Hospital, Beijing 100853, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yun Cai
Center of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, 28 Fu Xing Road, Beijing 100853, People’s Republic of China
Objective: To evaluate the pharmacokinetics (PK), bioequivalence and safety profile of the recombinant human chorionic gonadotropin (r-hCG) injection formulation LZM003 (test drug) comparing with that of Ovidrel® (reference drug) in healthy Chinese subjects.
Methods: This is a randomized, single-blind, single-dose, two-arm and two-period crossover Phase I study. Subjects were randomized evenly to a single dose of LZM003 or reference drug injected subcutaneously, with a 10-day or longer between-treatment washout period. PK parameters, anti-drug antibodies (ADAs), and adverse events (AEs) were assessed. The primary PK endpoints were area under the curve (AUC) of the concentration–time curve from zero to last quantifiable concentration (AUC0-t), AUC from zero to infinity (AUC0-∞), and peak concentration (Cmax). Bioequivalence was determined by assessing whether the 90% confidence intervals (CIs) for the geometric mean ratio (GMR) of LZM003 to reference drug fell within predefined margins of 80% − 125%.
Results: Forty-eight subjects (24 males and 24 females) were enrolled and one subject withdrew for personal reasons. Mean values of primary PK parameters were similar (p > 0.05) between LZM003 and the reference drug. The 90% CIs for primary PK endpoints’ GMR of LZM003 to reference drug ranged between 0.9144 and 1.1845, which were within bioequivalence margins of 80− 125%. Incidence of AEs was similar (p > 0.05) between the two groups. Neither LZM003 nor reference drug produced anti-drug antibody (ADA) in healthy subjects.
Conclusion: LZM003 and reference drug were bioequivalent. The PK and safety assessments were similar (p > 0.05) between the two formulations in healthy Chinese subjects.
Trial Registration Number: ChiCTR-IIR-16010158 (http://www.chictr.org.cn).
Trial Registration Date: December 15, 2016.
Keywords: bioequivalence, human chorionic gonadotropin, Chinese subject, pharmacokinetics
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]